US2014120107A1PendingUtilityA1

Genes of an otitis media isolate of nontypeable haemophilus influenzae

64
Individually held — no corporate assignee on recordPriority: Mar 6, 2003Filed: Dec 23, 2013Published: May 1, 2014
Est. expiryMar 6, 2023(expired)· nominal 20-yr term from priority
Inventors:Lauren O. BakaletzRobert S. Munson, Jr.David W. Dyer
A61P 37/04A61P 31/12C12N 15/113A61P 27/16C07K 14/285C12Q 1/689A61P 31/00A61P 31/04C07K 16/1242A61K 38/00G01N 33/56911A61K 39/00
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . An isolated polynucleotide comprising the nucleotide sequence of any one of SEQ ID NOS: 577-579, SEQ ID NOS: 589-614, SEQ ID NOS: 675-685, SEQ ID NO: 615, SEQ ID NO: 617, SEQ ID NO: 619, SEQ ID NO: 621, SEQ ID NO: 623, SEQ ID NO: 625, SEQ ID NO: 627, SEQ ID NO: 629, SEQ ID NO: 631, SEQ ID NO: 633, SEQ ID NO: 635, SEQ ID NO: 637, SEQ ID NO: 639, SEQ ID NO: 641, SEQ ID NO: 643, SEQ ID NO: 645, SEQ ID NO: 647, SEQ ID NO: 649, SEQ ID NO: 651, SEQ ID NO: 653, SEQ ID NO: 655, SEQ ID NO: 657, SEQ ID NO: 659, SEQ ID NO: 661, SEQ ID NO: 663, SEQ ID NO: 665. SEQ ID NO: 667, SEQ ID NO: 669, 671, SEQ ID NO: 673, SEQ ID NO: 686, SEQ ID NO: 688, SEQ ID NO: 692, SEQ ID NO: 694, SEQ ID NO: 696, SEQ ID NO: 698, SEQ ID NO: 700, SEQ ID NO: 702, SEQ ID NO: 704, SEQ ID NO: 706, SEQ ID NO: 708. SEQ ID NO: 710, SEQ ID NO: 712, SEQ ID NO: 714, SEQ ID NO: 716, SEQ ID NO: 718, SEQ ID NO: 720, SEQ ID NO: 722, SEQ ID NO: 724, SEQ ID NO:726, SEQ ID NO: 728, SEQ ID NO: 730, SEQ ID NO: 732, SEQ ID NO: 734, SEQ ID NO: 736, SEQ ID NO: 738, SEQ ID NO: 740, SEQ ID NO: 742, SEQ ID NO: 744, SEQ ID NO: 746, SEQ ID NO: 748, SEQ ID NO: 750, SEQ ID NO: 752, SEQ ID NO: 754, SEQ ID NO: 756, SEQ ID NO:758, SEQ ID NO:760, SEQ ID NO: 762, SEQ ID NO: 764, SEQ ID NO: 766, SEQ ID NO:768 or SEQ ID NO: 770. 
     
     
         2 . An isolated polypeptide comprising an amino acid sequence encoded by a nucleotide sequence set of  claim 1  or a fragment thereof. 
     
     
         3 . An isolated polypeptide comprising an amino acid sequence of any one of SEQ ID NO: 616, SEQ ID NO: 618, SEQ ID NO: 620, SEQ ID NO: 622, SEQ ID NO: 624, SEQ ID NO: 626, SEQ ID NO: 628, SEQ ID NO: 628, SEQ ID NO: 630, SEQ ID NO: 632, SEQ ID NO: 634, SEQ ID NO: 636, SEQ ID NO: 638, SEQ ID NO: 640, SEQ ID NO: 642, SEQ ID NO: 644, SEQ ID NO: 646, SEQ ID NO: 648, SEQ ID NO: 650, SEQ ID NO: 652, SEQ ID NO: 654, SEQ ID NO: 656, SEQ ID NO: 658, SEQ ID NO: 660, SEQ ID NO: 662, SEQ ID NO: 664, SEQ ID NO: 666. SEQ ID NO: 668, SEQ ID NO: 670, SEQ ID NO: 672, SEQ ID NO: 674, SEQ ID NO: 687, SEQ ID NO: 689, SEQ ID NO: 691, SEQ ID NO: 693, SEQ ID NO: 695. SEQ ID NO: 697, SEQ ID NO: 699, SEQ ID NO: 701, SEQ ID NO: 703, SEQ ID NO: 705. SEQ ID NO: 707. SEQ ID NO: 709. SEQ ID NO: 711. SEQ ID NO: 713 SEQ) ID NO: 715, SEQ ID NO: 717, SEQ ID NO: 719, SEQ ID NO: 721, SEQ ID NO:723. SEQ ID NO:725, SEQ ID NO:727, SEQ ID NO:729, SEQ ID NO: 731, SEQ ID NO: 733, SEQ ID NO: 715, SEQ ID NO: 737, SEQ ID NO: 739, SEQ ID NO: 741, SEQ ID NO: 743, SEQ ID NO: 745, SEQ ID NO: 747, SEQ ID NO: 749, SEQ ID NO: 751, SEQ ID NO: 753, SEQ ID NO: 755, SEQ ID NO: 757, SEQ ID NO: 759, SEQ ID NO: 761, 763, SEQ ID NO: 765, SEQ ID NO: 767, SEQ ID NO: 769 or SEQ ID NO: 771. 
     
     
         4 . A composition comprising a polypeptide of  claim 2  or  3  and a pharmaceutically acceptable carrier. 
     
     
         5 . An antibody that specifically binds to a polypeptide of  claim 2  or  3  or fragment thereof. 
     
     
         6 . A composition comprising an antibody of  claim 5  and a pharmaceutically acceptable carrier. 
     
     
         7 . A method for detecting NTHi bacteria in a biological sample comprising
 (a) contacting a polynucleotide of  claim 1  or a fragment thereof with a biological sample, and   (b) detecting hybridization of the polynucleotide within the sample.   
     
     
         8 . A method for detecting NTHi bacteria in a biological sample comprising:
 (a) contacting an antibody of  claim 5  with a biological sample, and   (b) detecting binding of the antibody within the sample.   
     
     
         9 . The method of  claim 7  or  8  wherein the biological sample is selected from the group consisting of serum, sputum, ear fluid, blood, urine, lymphatic fluid, and cerebrospinal fluid. 
     
     
         10 . A method for eliciting an immune response to NTHi bacteria comprising administering an immunogenically effective dose of a polypeptide of  claim 2  or  3  or a fragment thereof to a patient at risk of NTHi bacterial infection. 
     
     
         11 . A vaccine comprising a polypeptide of  claim 2  or  3  or a fragment thereof and a pharmaceutically suitable carrier. 
     
     
         12 . A method for preventing NTHi bacterial infection comprising administering a polypeptide of  claim 2  or  3  that blocks cellular attachment of NTHi bacteria to a patient at risk of NTHi bacterial infection. 
     
     
         13 . A method for preventing NTHi bacterial infection comprising administering an antibody of  claim 5  that blocks cellular attachment of NTHi bacteria to a patient at risk of NTHi bacterial infection. 
     
     
         14 . The method of  claim 13  wherein the NTHi infection is in the middle ear. 
     
     
         15 . A method of treating or preventing NTHi bacterial infection comprising administering a molecule that inhibits expression or activity of a polypeptide of  claim 2  or  3  to an patient in need. 
     
     
         16 . The method of  claim 15  wherein the NTHi polypeptide comprises the is encoded by an NTHi gene selected from the group consisting of hisB, lppB, sapA, rbsC, pure, rib, arcB, uxuA, licC, ispZ, mukF, glpR, ihfB, cspD, lav, HI1647, HI0094, HI1163, HI10665, HI1292, HI1064, HI1386, HI1462, HI11369, and HI1598. 
     
     
         17 . The method of  claim 15  wherein the NTHi polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 616, SEQ ID NO: 618, SEQ ID NO: 620, SEQ ID NO: 622, SEQ ID NO: 624, SEQ ID NO: 626, SEQ ID NO: 628, SEQ ID NO: 634, SEQ ID NO: 638, SEQ ID NO: 642, SEQ ID NO: 644, SEQ ID NO: 646, SEQ ID NO: 650, SEQ ID NO: 652, SEQ ID NO: 656, SEQ ID NO: 658, SEQ ID NO: 660, SEQ ID NO: 662, SEQ ID NO: 664, SEQ ID NO: 666, SEQ ID NO: 668, SEQ ID NO: 670, SEQ ID NO:672 and SEQ ID NO: 674. 
     
     
         18 . The method of  claim 15  wherein the molecule administered to the patient in need is an antisense oligonucleotide. 
     
     
         19 . The method of  claim 15  wherein the molecule administered to the patient in need is an antibody. 
     
     
         20 . The method of  claim 15  wherein the molecule administered to the patient in need is a small molecule. 
     
     
         21 . The method of  claims 15  wherein the NTHi infection is in the middle ear.

Join the waitlist — get patent alerts

Track US2014120107A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.